OMV Engineering Services for CAR-T Infiltration

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

Although CAR-T therapy has achieved notable success in blood cancers, its efficacy against solid tumors is often compromised by inadequate T-cell trafficking, a hostile tumor microenvironment (TME), and frequent antigen loss. Creative Biolabs' OMV Engineering Services for CAR-T Infiltration tackle these obstacles, promoting effective CAR-T localization, sustained activation, and long-term intratumoral persistence. Through advanced engineering strategies and multivalent antigen display systems, we repurpose OMVs as tailored immune modulators that reshape the TME and direct CAR-T cells toward complete tumor eradication.

Introduction

Outer membrane vesicle (OMV) engineering involves the genetic and biochemical modification of bacterial-derived nanoscale vesicles to serve as customizable drug delivery platforms. By leveraging their native immunostimulatory properties and high surface functionalization capacity, OMV engineering facilitates targeted CAR-T cell infiltration into solid tumors through enhanced chemokine-guided trafficking and extracellular matrix remodeling.

Fig.1 Advanced OMV engineering to enable CAR-T infiltration efficacy. (Creative Biolabs Original) Fig.1 Engineered OMV solutions for enhanced CAR-T tumor infiltration.

OMV Engineering Services for CAR-T Infiltration at Creative Biolabs

Solid tumors rely on a dense combination of physical barriers and immunosuppressive signals. Creative Biolabs offers a modular OMV platform designed to enhance the functional impact of CAR-T cells. Our engineered vesicles can mark antigen-negative tumor cells for recognition, suppress checkpoint pathways through RNA interference, and break down stromal components to facilitate deeper T cell infiltration. Collaborating with us provides access to a flexible delivery system that shifts cold tumors into a state of strong immune visibility and responsiveness.

Service Packages

OMV Strain Engineering for Enhanced CAR-T Adjuvant Potency

This service focuses on genetically modifying bacterial strains to produce OMVs with optimized immunostimulatory properties. By engineering the lipid structure and endogenous adjuvant payloads, the resulting OMVs potently activate CAR-T cells within the tumor microenvironment, enhancing their proliferation, persistence, and cytotoxic function.

Learn More →

OMV Surface Engineering for Precision CAR-T Homing & Synapse

This service describes the functionalization of OMV surfaces with targeting ligands to guide CAR-T cells precisely to tumor sites. Additionally, surface engineering can be designed to stabilize the immunological synapse between CAR-T cells and target cancer cells, ensuring efficient killing while reducing off-tumor toxicity.

Learn More →

In Vivo Antigen Programming for Universal CAR-T Targeting (BROAD-CAR)

This service introduces a transformative platform where OMVs are used to transiently program tumor cells or antigen-presenting cells in vivo to display synthetic or neo-antigens, which are then recognized by a universal CAR-T construct (BROAD-CAR). This approach eliminates the need for custom CAR engineering per patient, enabling rapid, off-the-shelf targeting of diverse cancers.

Learn More →

Our Service Process

Required Starting Materials:

The target tumor antigen sequences.
Specific therapeutic payloads.
Preferred bacterial strain requirements.

Key Steps:

Workflow of OMV engineering services for CAR-T infiltration at Creative Biolabs. (Creative Biolabs Original)

Estimated Timeframe: The typical timeframe for this service ranges from 8 to 12 weeks, depending on the complexity of the surface decoration and the specific payload requirements.

Key Advantages

Superior Payload Capacity: Our OMV platform delivers a higher loading capacity compared to traditional synthetic liposomes, enabling more efficient delivery of therapeutic agents.
Intrinsic Immunogenicity: Unlike synthetic carriers, OMVs possess natural immune-activating properties, which enhance CAR-T cell priming and anti-tumor responses without external adjuvants.
Enhanced Safety Profile: By utilizing genetically engineered strains with detoxified LPS, we minimize systemic inflammation while preserving potent adjuvant activity, balancing efficacy and safety.

FAQs

Q1: What measures are taken to guarantee the safety of vesicles derived from bacterial sources?

A1: Our approach relies on genetically weakened bacterial strains combined with engineered lipid structures. This design minimizes endotoxin-related risks while keeping the immunostimulatory features needed to draw T cells into the tumor microenvironment.

Q2: Which types of therapeutic or diagnostic payloads can be packaged inside OMVs?

A2: Our platform supports a broad range of cargo, including mRNA for protein replacement, siRNA for gene silencing, conventional small-molecule chemotherapeutics, and molecular imaging probes. Both passive diffusion and active encapsulation techniques are available to achieve efficient loading depending on the payload properties.

Why Choose Us

Unlock superior CAR-T infiltration with our engineered OMV platform, offering higher payload capacity, intrinsic immunogenicity, and detoxified LPS for enhanced safety. Backed by published data showing significantly greater therapeutic RNA enrichment than standard vesicles, we deliver unmatched stability, precision, and efficacy for advanced cell therapy applications.

How to contact us?

At Creative Biolabs, we offer a complete OMV engineering solution tailored to break through key obstacles in solid tumor immunotherapy. Whether through multivalent antigen surface display or RNA-driven reversal of treatment resistance, our platform empowers your CAR-T therapy to achieve its maximum clinical promise.

Reach out to our team for further details or to explore your project needs.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.